Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Citius Pharmaceuticals develops proprietary critical care and dermatological products, including Mino-Lok for catheter infection salvage, Halo-Lido for hemorrhoid relief, and NoveCite stem cell therapy for ARDS. The company focuses on reformulations of approved drugs with strong safety data, targeting large, underserved markets. It leverages regulatory exclusivity, innovative applications, and strategic licensing to provide effective, lower-risk therapeutic solutions.
This description was generated via AI from an annual report. Updated about 1 year ago.